LXEO Lexeo Therapeutics, Inc.
Financings ·
Lexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced.
Lexeo paid $5,300,000 in cash and $3,000,000 in common stock upfront. Up to $12,000,000 in milestones and a $1,000,000 cash payment are not guaranteed.
Lexeo agrees to sell 15,625,000 shares for expected gross proceeds of approximately $125 million. A concurrent private placement of pre-funded warrants is expected to bring approximately $10 million.
Lexeo Therapeutics agreed to a private placement of 20,790,120 shares and pre-funded warrants for 6,963,556 more, with common warrants attached, for gross proceeds the company expects to be about $80 million. Part of that figure depends on warrants that have not been exercised, and the runway it cites depends on a 2027 readout.
Lexeo expects gross proceeds of approximately $80 million from 20,790,120 shares or pre-funded warrants at $2.8825, with common warrants struck at $2.82.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $63.8 million | $74.1 million |
| Net income (loss) | -$100.0 million | -$98.3 million |
| Cash from operations | -$98.6 million | -$81.2 million |
| Cash and equivalents | $63.0 million | $35.0 million |
| Short-term investments | $118.8 million | $86.5 million |
Our latest story on this, dated Oct 29, 2026: "Lexeo Therapeutics files $300 million shelf registration". The story links the filing or release it is based on. Read the story.
Lexeo Therapeutics, Inc. trades under the ticker LXEO on NASDAQ.
Lexeo Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Lexeo Therapeutics, Inc. is 1907108. Its filings are on SEC EDGAR.
82,046,255 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Lexeo Therapeutics, Inc. under United States.
Our directory classifies Lexeo Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lexeo Therapeutics, Inc. is US52886X1072.
aibio.space lists Lexeo Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Lexeo Therapeutics, Inc. reported a net loss of $100.0 million for the fiscal year ended Dec 31, 2025, and used $98.6 million of cash in operations, per its annual report to the SEC.
$63.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$211.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Lexeo Therapeutics, dated Oct 29, 2026: "Lexeo Therapeutics files $300 million shelf registration". Lexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced. Source.
From our story of May 27, 2025: The press release headline says the cash runway extends into 2028, and that the proceeds will fund operations through a potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy. Source.
Our latest merger story, dated Sep 29, 2026: "Lexeo completes Mantle Therapeutics deal for $5,300,000 cash plus $3,000,000 in stock". Lexeo paid $5,300,000 in cash and $3,000,000 in common stock upfront. Up to $12,000,000 in milestones and a $1,000,000 cash payment are not guaranteed. Source.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio